Update on the roles of distal airways in COPD

European Respiratory Review

Volumn 20, Issue 119, 2011, Pages 7-22

  Burgel, P R ^a   Bourdin, A ^b   Chanez, P ^c   Chabot, F ^d   Chaouat, A ^d   Chinet, T ^e   de Blic, J ^f   Devillier, P ^g   Deschildre, A ^h   Didier, A ⁱ   Garcia, G ^j   Jebrak, G ^k   Laurent, F ^l   Morel, H ^m   Perez, T ^h   Pilette, C ⁿ   Roche, N ^o   Tillie Leblond, I ^h   Verbanck, S ^p   Dusser, D ^a  

^a université Paris Cité   (France)

^b HÔPITAL ARNAUD DE VILLENEUVE   (France)

^c HÔPITAL SAINTE MARGUERITE   (France)

^d CHU NANCY BRABOIS   (France)

^e HÔPITAL AMBROISE PARÉ   (France)

^f HÔPITAL NECKER ENFANTS MALADES   (France)

^g UPRES EA 220   (France)

^h LILLE UNIVERSITY HOSPITAL   (France)

ⁱ UNIVERSITÉ DE TOULOUSE   (France)

^j HÔPITAL ANTOINE BÉCLÈRE   (France)

^k BICHAT HOSPITAL   (France)

^l BORDEAUX UNIVERSITY HOSPITAL   (France)

^m Université catholique de Louvain ^*  (France)

ⁿ CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^o HÔTEL DIEU   (France)

^p UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

more..

Author keywords

Airway inflammation; Airway remodelling; Alveoli; Bronchioles; Chronic obstructive pulmonary disease; Distal airways

Indexed keywords

ACETYLCYSTEINE; BECLOMETASONE; BECLOMETASONE DIPROPIONATE PLUS FORMOTEROL; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE PLUS FORMOTEROL; FORMOTEROL; PLACEBO; ROFLUMILAST; STEROID; THEOPHYLLINE; UNCLASSIFIED DRUG;

AIRWAY REMODELING; AIRWAY RESISTANCE; B LYMPHOCYTE; BODY PLETHYSMOGRAPHY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CIGARETTE SMOKING; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DENDRITIC CELL; DISEASE COURSE; DYSPNEA; EX VIVO STUDY; FIBEROPTIC BRONCHOSCOPY; FRANCE; HISTOPATHOLOGY; HUMAN; LUNG ALVEOLUS; LUNG BIOPSY; LUNG EMPHYSEMA; LUNG FUNCTION; LUNG INFILTRATE; MACROPHAGE; MORTALITY; NEUTROPHIL; NITROGEN WASHOUT; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OSCILLATION; PATHOPHYSIOLOGY; PHAGOCYTE; PULMONARY ARTERY MALFORMATION; QUALITY OF LIFE; RESPIRATORY EPITHELIUM; RESPIRATORY TRACT INFLAMMATION; REVIEW; SPIROMETRY; SYMPOSIUM; T LYMPHOCYTE;

AIRWAY REMODELING; AIRWAY RESISTANCE; CONGRESSES AS TOPIC; DIAGNOSTIC IMAGING; HUMANS; LUNG; PREDICTIVE VALUE OF TESTS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATORY FUNCTION TESTS;

EID: 79952372816     PISSN: 09059180     EISSN: None     Source Type: Journal    
DOI: 10.1183/09059180.10010610     Document Type: Review

References (176)

1. Hogg JC, Macklem PT, Thurlbeck WM. Site and nature of airway obstruction in chronic obstructive lung disease. N Engl J Med 1968; 278: 1355-1360.
2. Yanai M, Sekizawa K, Ohrui T, et al. Site of airway obstruction in pulmonary disease: direct measurement of intrabronchial pressure. J Appl Physiol 1992; 72: 1016-1023.
3. Leach C, Colice GL, Luskin A. Particle size of inhaled corticosteroids: does it matter? J Allergy Clin Immunol 2009; 124: Suppl. 6, S88-S93.
4. Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356: 775-789.
5. Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008; 359: 1543-1554.
6. Alifano M, Cuvelier A, Delage A, et al. Treatment of COPD: from pharmacological to instrumental therapies. Eur Respir Rev 2010; 19: 7-23.
7. Burgel P-R, de Blic J, Chanez P, et al. Update on the roles of distal airways in asthma. Eur Respir Rev 2009; 18: 80-95.
8. Hogg JC, Chu F, Utokaparch S, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 2004; 350: 2645-2653.
9. Cosio M, Ghezzo H, Hogg JC, et al. The relations between structural changes in small airways and pulmonary-function tests. N Engl J Med 1978; 298: 1277-1281.
10. Lofdahl JM, Wahlstrom J, Skold CM. Different inflammatory cell pattern and macrophage phenotype in chronic obstructive pulmonary disease patients, smokers and non-smokers. Clin Exp Immunol 2006; 145: 428-437.
11. Lofdahl JM, Cederlund K, Nathell L, et al. Bronchoalveolar lavage in COPD: fluid recovery correlates with the degree of emphysema. Eur Respir J 2005; 25: 275-281.
12. Thiberville L, Salaun M, Lachkar S, et al. Human in vivo fluorescence microimaging of the alveolar ducts and sacs during bronchoscopy. Eur Respir J 2009; 33: 974-985.
13. Bergeron C, Tulic MK, Hamid Q. Tools used to measure airway remodelling in research. Eur Respir J 2007; 29: 596-604.
14. Persson MG, Zetterstrom O, Agrenius V, et al. Single-breath nitric oxide measurements in asthmatic patients and smokers. Lancet 1994; 343: 146-147.
15. Lehouck A, Carremans C, De Bent K, et al. Alveolar and bronchial exhaled nitric oxide in chronic obstructive pulmonary disease. Respir Med 2010; 104: 1020-1026.
16. Borrill ZL, Roy K, Singh D. Exhaled breath condensate biomarkers in COPD. Eur Respir J 2008; 32: 472-486.
17. Peters EJ, Morice R, Benner SE, et al. Squamous metaplasia of the bronchial mucosa and its relationship to smoking. Chest 1993; 103: 1429-1432.
18. Lapperre TS, Sont JK, van Schadewijk A, et al. Smoking cessation and bronchial epithelial remodelling in COPD: a cross-sectional study. Respir Res 2007; 8: 85.
19. Araya J, Cambier S, Markovics JA, et al. Squamous metaplasia amplifies pathologic epithelial-mesenchymal interactions in COPD patients. J Clin Invest 2007; 117: 3551-3562.
20. Innes AL, Woodruff PG, Ferrando RE, et al. Epithelial mucin stores are increased in the large airways of smokers with airflow obstruction. Chest 2006; 130: 1102-1108.
21. O'Donnell RA, Richter A, Ward J, et al. Expression of ErbB receptors and mucins in the airways of long term current smokers. Thorax 2004; 59: 1032-1040.
22. Cosio MG, Hale KA, Niewoehner DE. Morphologic and morphometric effects of prolonged cigarette smoking on the small airways. Am Rev Respir Dis 1980; 122: 265-221.
23. Nagai A, West WW, Thurlbeck WM. The National Institutes of Health Intermittent Positive-Pressure Breathing trial: pathology studies. II. Correlation between morphologic findings, clinical findings, and evidence of expiratory air-flow obstruction. Am Rev Respir Dis 1985; 132: 946-953.
24. Niewoehner DE, Kleinerman J, Rice DB. Pathologic changes in the peripheral airways of young cigarette smokers. N Engl J Med 1974; 291: 755-758.
25. Saetta M, Turato G, Baraldo S, et al. Goblet cell hyperplasia and epithelial inflammation in peripheral airways of smokers with both symptoms of chronic bronchitis and chronic airflow limitation. Am J Respir Crit Care Med 2000; 161: 1016-1021.
26. Caramori G, Di Gregorio C, Carlstedt I, et al. Mucin expression in peripheral airways of patients with chronic obstructive pulmonary disease. Histopathology 2004; 45: 477-484.
27. Hale KA, Ewing SL, Gosnell BA, et al. Lung disease in long-term cigarette smokers with and without chronic air-flow obstruction. Am Rev Respir Dis 1984; 130: 716-721.
28. Mitchell RS, Stanford RE, Johnson JM, et al. The morphologic features of the bronchi, bronchioles, and alveoli in chronic airway obstruction: a clinicopathologic study. Am Rev Respir Dis 1976; 114: 137-145.
29. Burgel PR, Nadel JA. Epidermal growth factor receptor-mediated innate immune responses and their roles in airway diseases. Eur Respir J 2008; 32: 1068-1081.
30. de Boer WI, Sont JK, van Schadewijk A, et al. Monocyte chemoattractant protein 1, interleukin 8, and chronic airways inflammation in COPD. J Pathol 2000; 190: 619-626.
31. Fuke S, Betsuyaku T, Nasuhara Y, et al. Chemokines in bronchiolar epithelium in the development of chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol 2004; 31: 405-412.
32. Saetta M, Mariani M, Panina-Bordignon P, et al. Increased expression of the chemokine receptor CXCR3 and its ligand CXCL10 in peripheral airways of smokers with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002; 165: 1404-1409.
33. Takizawa H, Tanaka M, Takami K, et al. Increased expression of inflammatory mediators in small-airway epithelium from tobacco smokers. Am J Physiol Lung Cell Mol Physiol 2000; 278: L906-L913.
34. Thurlbeck WM. Pathophysiology of chronic obstructive pulmonary disease. Clin Chest Med 1990; 11: 389-403.
35. Wright JL, Postma DS, Kerstjens HA, et al. Airway remodeling in the smoke exposed guinea pig model. Inhal Toxicol 2007; 19: 915-923.
36. Churg A, Tai H, Coulthard T, et al. Cigarette smoke drives small airway remodeling by induction of growth factors in the airway wall. Am J Respir Crit Care Med 2006; 174: 1327-1334.
37. Churg A, Zhou S, Preobrazhenska O, et al. Expression of profibrotic mediators in small airways versus parenchyma after cigarette smoke exposure. Am J Respir Cell Mol Biol 2009; 40: 268-276.
38. Ning W, Li CJ, Kaminski N, et al. Comprehensive gene expression profiles reveal pathways related to the pathogenesis of chronic obstructive pulmonary disease. Proc Natl Acad Sci USA 2004; 101: 14895-14900.
39. Wang IM, Stepaniants S, Boie Y, et al. Gene expression profiling in patients with chronic obstructive pulmonary disease and lung cancer. Am J Respir Crit Care Med 2008; 177: 402-411.
40. Gaga M, Zervas E, Chanez P. Update on severe asthma: what we know and what we need. Eur Respir Rev 2009; 18: 58-65.
41. Corsico A, Milanese M, Baraldo S, et al. Small airway morphology and lung function in the transition from normality to chronic airway obstruction. J Appl Physiol 2003; 95: 441-447.
42. Aikawa T, Shimura S, Sasaki H, et al. Morphometric analysis of intraluminal mucus in airways in chronic obstructive pulmonary disease. Am Rev Respir Dis 1989; 140: 477-482.
43. MacNee W. Pathogenesis of chronic obstructive pulmonary disease. Proc Am Thorac Soc 2005; 2: 258-266.
44. Saetta M, Ghezzo H, Kim WD, et al. Loss of alveolar attachments in smokers. A morphometric correlate of lung function impairment. Am Rev Respir Dis 1985; 132: 894-900.
45. Tsuji T, Aoshiba K, Nagai A. Alveolar cell senescence in patients with pulmonary emphysema. Am J Respir Crit Care Med 2006; 174: 886-893.
46. Imai K, Mercer BA, Schulman LL, et al. Correlation of lung surface area to apoptosis and proliferation in human emphysema. Eur Respir J 2005; 25: 250-258.
47. Kasahara Y, Tuder RM, Cool CD, et al. Endothelial cell death and decreased expression of vascular endothelial growth factor and vascular endothelial growth factor receptor 2 in emphysema. Am J Respir Crit Care Med 2001; 163: 737-744.
48. Majo J, Ghezzo H, Cosio MG. Lymphocyte population and apoptosis in the lungs of smokers and their relation to emphysema. Eur Respir J 2001; 17: 946-953.
49. Yokohori N, Aoshiba K, Nagai A. Increased levels of cell death and proliferation in alveolar wall cells in patients with pulmonary emphysema. Chest 2004; 125: 626-632.
50. Calabrese F, Giacometti C, Beghe B, et al. Marked alveolar apoptosis/proliferation imbalance in end-stage emphysema. Respir Res 2005; 6: 14.
51. Feghali-Bostwick CA, Gadgil AS, Otterbein LE, et al. Autoantibodies in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008; 177: 156-163.
52. Cosio MG, Saetta M, Agusti A. Immunologic aspects of chronic obstructive pulmonary disease. N Engl J Med 2009; 360: 2445-2454.
53. Black PN, Ching PS, Beaumont B, et al. Changes in elastic fibres in the small airways and alveoli in COPD. Eur Respir J 2008; 31: 998-1004.
54. Hogg JC, Pierce RA. Remodelling of peripheral lung tissue in COPD. Eur Respir J 2008; 31: 913-914.
55. Hogg JC, McDonough JE, Sanchez PG, et al. Micro-computed tomography measurements of peripheral lung pathology in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2009; 6: 546-549.
56. Santos S, Peinado VI, Ramirez J, et al. Characterization of pulmonary vascular remodelling in smokers and patients with mild COPD. Eur Respir J 2002; 19: 632-638.
57. Magee F, Wright JL, Wiggs BR, et al. Pulmonary vascular structure and function in chronic obstructive pulmonary disease. Thorax 1988; 43: 183-189.
58. Barbera JA, Peinado VI, Santos S. Pulmonary hypertension in chronic obstructive pulmonary disease. Eur Respir J 2003; 21: 892-905.
59. Hogg JC, Timens W. The pathology of chronic obstructive pulmonary disease. Annu Rev Pathol 2009; 4: 435-459.
60. Turato G, Zuin R, Miniati M, et al. Airway inflammation in severe chronic obstructive pulmonary disease: relationship with lung function and radiologic emphysema. Am J Respir Crit Care Med 2002; 166: 105-110.
61. Saetta M, Turato G, Maestrelli P, et al. Cellular and structural bases of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 163: 1304-1309.
62. O'Donnell RA, Peebles C, Ward JA, et al. Relationship between peripheral airway dysfunction, airway obstruction, and neutro-philic inflammation in COPD. Thorax 2004; 59: 837-842.
63. Nadel JA. Role of neutrophil elastase in hypersecretion during COPD exacerbations, and proposed therapies. Chest 2000; 117: Suppl. 2, 386S-389S.
64. Finkelstein R, Ma HD, Ghezzo H, et al. Morphometry of small airways in smokers and its relationship to emphysema type and hyperresponsiveness. Am J Respir Crit Care Med 1995; 152: 267-276.
65. Frankenberger M, Menzel M, Betz R, et al. Characterization of a population of small macrophages in induced sputum of patients with chronic obstructive pulmonary disease and healthy volunteers. Clin Exp Immunol 2004; 138: 507-516.
66. di Stefano A, Capelli A, Lusuardi M, et al. Severity of airflow limitation is associated with severity of airway inflammation in smokers. Am J Respir Crit Care Med 1998; 158: 1277-1285.
67. Saetta M, Di Stefano A, Maestrelli P, et al. Activated T-lymphocytes and macrophages in bronchial mucosa of subjects with chronic bronchitis. Am Rev Respir Dis 1993; 147: 301-306.
68. Lams BE, Sousa AR, Rees PJ, et al. Immunopathology of the small-airway submucosa in smokers with and without chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 158: 1518-1523.
69. O'Shaughnessy TC, Ansari TW, Barnes NC, et al. Inflammation in bronchial biopsies of subjects with chronic bronchitis: inverse relationship of CD8+ T lymphocytes with FEV1. Am J Respir Crit Care Med 1997; 155: 852-857.
70. Saetta M, Di Stefano A, Turato G, et al. CD8+ T-lymphocytes in peripheral airways of smokers with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 157: 822-826.
71. Saetta M, Baraldo S, Corbino L, et al. CD8+ve cells in the lungs of smokers with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 160: 711-717.
72. Roos-Engstrand E, Ekstrand-Hammarstrom B, Pourazar J, et al. Influence of smoking cessation on airway T lymphocyte subsets in COPD. COPD 2009; 6: 112-120.
73. Barcelo B, Pons J, Ferrer JM, et al. Phenotypic characterisation of T-lymphocytes in COPD: abnormal CD4+CD25+ regulatory T-lymphocyte response to tobacco smoking. Eur Respir J 2008; 31: 555-562.
74. Retamales I, Elliott WM, Meshi B, et al. Amplification of inflammation in emphysema and its association with latent adenoviral infection. Am J Respir Crit Care Med 2001; 164: 469-473.
75. Enelow RI, Mohammed AZ, Stoler MH, et al. Structural and functional consequences of alveolar cell recognition by CD8(+) T lymphocytes in experimental lung disease. J Clin Invest 1998; 102: 1653-1661.
76. Fairclough L, Urbanowicz RA, Corne J, et al. Killer cells in chronic obstructive pulmonary disease. Clin Sci (Lond) 2008; 114: 533-541.
77. Vernooy JH, Moller GM, van Suylen RJ, et al. Increased granzyme A expression in type II pneumocytes of patients with severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007; 175: 464-472.
78. Domagala-Kulawik J, Hoser G, Dabrowska M, et al. Increased proportion of Fas positive CD8+ cells in peripheral blood of patients with COPD. Respir Med 2007; 101: 1338-1343.
79. Kim V, Kelemen SE, Abuel-Haija M, et al. Small airway mucous metaplasia and inflammation in chronic obstructive pulmonary disease. COPD 2008; 5: 329-338.
80. Casolaro MA, Bernaudin JF, Saltini C, et al. Accumulation of Langerhans' cells on the epithelial surface of the lower respiratory tract in normal subjects in association with cigarette smoking. Am Rev Respir Dis 1988; 137: 406-411.
81. Soler P, Moreau A, Basset F, et al. Cigarette smoking-induced changes in the number and differentiated state of pulmonary dendritic cells/Langerhans cells. Am Rev Respir Dis 1989; 139: 1112-1117.
82. Demedts IK, Bracke KR, Van Pottelberge G, et al. Accumulation of dendritic cells and increased CCL20 levels in the airways of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007; 175: 998-1005.
83. Freeman CM, Martinez FJ, Han MK, et al. Lung dendritic cell expression of maturation molecules increases with worsening chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009; 180: 1179-1188.
84. Tsoumakidou M, Koutsopoulos AV, Tzanakis N, et al. Decreased small airway and alveolar CD83+ dendritic cells in COPD. Chest 2009; 136: 726-733.
85. Rogers AV, Adelroth E, Hattotuwa K, et al. Bronchial mucosal dendritic cells in smokers and ex-smokers with COPD: an electron microscopic study. Thorax 2008; 63: 108-114.
86. Tsoumakidou M, Bouloukaki I, Koutala H, et al. Decreased sputum mature dendritic cells in healthy smokers and patients with chronic obstructive pulmonary disease. Int Arch Allergy Immunol 2009; 150: 389-397.
87. Grashoff WF, Sont JK, Sterk PJ, et al. Chronic obstructive pulmonary disease: role of bronchiolar mast cells and macro-phages. Am J Pathol 1997; 151: 1785-1790.
88. Andersson CK, Mori M, Bjermer L, et al. Alterations in lung mast cell populations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2010; 181: 206-217.
89. Saetta M, Di Stefano A, Maestrelli P, et al. Airway eosinophilia in chronic bronchitis during exacerbations. Am J Respir Crit Care Med 1994; 150: 1646-1652.
90. Papi A, Bellettato CM, Braccioni F, et al. Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. Am J Respir Crit Care Med 2006; 173: 1114-1121.
91. Snoeck-Stroband JB, Lapperre TS, Gosman MM, et al. Chronic bronchitis sub-phenotype within COPD: inflammation in sputum and biopsies. Eur Respir J 2008; 31: 70-77.
92. Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007; 176: 532-555.
93. Bourdin A, Burgel PR, Chanez P, et al. Recent advances in COPD: pathophysiology, respiratory physiology and clinical aspects, including comorbidities. Eur Respir Rev 2009; 18: 198-212.
94. McFadden ER Jr, Linden DA. A reduction in maximum mid-expiratory flow rate. A spirographic manifestation of small airway disease. Am J Med 1972; 52: 725-737.
95. Hansen JE, Sun XG, Wasserman K. Discriminating measures and normal values for expiratory obstruction. Chest 2006; 129: 369-377.
96. Knudson RJ, Lebowitz MD. Maximal mid-expiratory flow (FEF25-75%): normal limits and assessment of sensitivity. Am Rev Respir Dis 1978; 117: 609-610.
97. Sorkness RL, Bleecker ER, Busse WW, et al. Lung function in adults with stable but severe asthma: air trapping and incomplete reversal of obstruction with bronchodilation. J Appl Physiol 2008; 104: 394-403.
98. O'Donnell DE. Hyperinflation, dyspnea, and exercise intolerance in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2006; 3: 180-184.
99. Corbin RP, Loveland M, Martin RR, et al. A four-year follow-up study of lung mechanics in smokers. Am Rev Respir Dis 1979; 120: 293-304.
100. Macklem PT. Therapeutic implications of the pathophysiology of COPD. Eur Respir J 2010; 35: 676-680.
101. Ferguson GT. Why does the lung hyperinflate? Proc Am Thorac Soc 2006; 3: 176-179.
102. Kim WD, Ling SH, Coxson HO, et al. The association between small airway obstruction and emphysema phenotypes in COPD. Chest 2007; 131: 1372-1378.
103. Garcia-Rio F, Lores V, Mediano O, et al. Daily physical activity in patients with chronic obstructive pulmonary disease is mainly associated with dynamic hyperinflation. Am J Respir Crit Care Med 2009; 180: 506-512.
104. O'Donnell DE, Bertley JC, Chau LK, et al. Qualitative aspects of exertional breathlessness in chronic airflow limitation: patho-physiologic mechanisms. Am J Respir Crit Care Med 1997; 155: 109-115.
105. Newton MF, O'Donnell DE, Forkert L. Response of lung volumes to inhaled salbutamol in a large population of patients with severe hyperinflation. Chest 2002; 121: 1042-1050.
106. O'Donnell DE, Revill SM, Webb KA. Dynamic hyperinflation and exercise intolerance in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 164: 770-777.
107. Ofir D, Laveneziana P, Webb KA, et al. Mechanisms of dyspnea during cycle exercise in symptomatic patients with GOLD stage I chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008; 177: 622-629.
108. Callens E, Graba S, Gillet-Juvin K, et al. Measurement of dynamic hyperinflation after a 6-minute walk test in patients with COPD. Chest 2009; 136: 1466-1472.
109. Marin JM, Carrizo SJ, Gascon M, et al. Inspiratory capacity, dynamic hyperinflation, breathlessness, and exercise performance during the 6-minute-walk test in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 163: 1395-1399.
110. O'Donnell DE, Voduc N, Fitzpatrick M, et al. Effect of salmeterol on the ventilatory response to exercise in chronic obstructive pulmonary disease. Eur Respir J 2004; 24: 86-94.
111. O'Donnell DE, Fluge T, Gerken F, et al. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J 2004; 23: 832-840.
112. Bassiri AG, Girgis RE, Doyle RL, et al. Detection of small airway dysfunction using specific airway conductance. Chest 1997; 111: 1533-1535.
113. Oostveen E, MacLeod D, Lorino H, et al. The forced oscillation technique in clinical practice: methodology, recommendations and future developments. Eur Respir J 2003; 22: 1026-1041.
114. Goldman MD, Saadeh C, Ross D. Clinical applications of forced oscillation to assess peripheral airway function. Respir Physiol Neurobiol 2005; 148: 179-194.
115. Johnson MK, Birch M, Carter R, et al. Use of reactance to estimate transpulmonary resistance. Eur Respir J 2005; 25: 1061-1069.
116. Di Mango AM, Lopes AJ, Jansen JM, et al. Changes in respiratory mechanics with increasing degrees of airway obstruction in COPD: detection by forced oscillation technique. Respir Med 2006; 100: 399-410.
117. Kolsum U, Borrill Z, Roy K, et al. Impulse oscillometry in COPD: identification of measurements related to airway obstruction, airway conductance and lung volumes. Respir Med 2009; 103: 136-143.
118. Kanda S, Fujimoto K, Komatsu Y, et al. Evaluation of respiratory impedance in asthma and COPD by an impulse oscillation system. Intern Med 2010; 49: 23-30.
119. Calverley PM, Koulouris NG. Flow limitation and dynamic hyperinflation: key concepts in modern respiratory physiology. Eur Respir J 2005; 25: 186-199.
120. Dellaca RL, Duffy N, Pompilio PP, et al. Expiratory flow limitation detected by forced oscillation and negative expiratory pressure. Eur Respir J 2007; 29: 363-374.
121. Dellaca RL, Santus P, Aliverti A, et al. Detection of expiratory flow limitation in COPD using the forced oscillation technique. Eur Respir J 2004; 23: 232-240.
122. Dellaca RL, Pompilio PP, Walker PP, et al. Effect of bronchodila-tion on expiratory flow limitation and resting lung mechanics in COPD. Eur Respir J 2009; 33: 1329-1337.
123. Paredi P, Goldman M, Alamen A, et al. Comparison of inspiratory and expiratory resistance and reactance in patients with asthma and chronic obstructive pulmonary disease. Thorax 2010; 65: 263-267.
124. Oppenheimer BW, Goldring RM, Berger KI. Distal airway function assessed by oscillometry at varying respiratory rate: comparison with dynamic compliance. COPD 2009; 6: 162-170.
125. Borrill ZL, Houghton CM, Tal-Singer R, et al. The use of plethysmography and oscillometry to compare long-acting bronchodilators in patients with COPD. Br J Clin Pharmacol 2008; 65: 244-252.
126. Borrill ZL, Houghton CM, Woodcock AA, et al. Measuring bronchodilation in COPD clinical trials. Br J Clin Pharmacol 2005; 59: 379-384.
127. Haruna A, Oga T, Muro S, et al. Relationship between peripheral airway function and patient-reported outcomes in COPD: a cross-sectional study. BMC Pulm Med 2010; 10: 10.
128. Stevenson NJ, Walker PP, Costello RW, et al. Lung mechanics and dyspnea during exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005; 172: 1510-1516.
129. Fregonese L, van Veen HP, Sterk PJ, et al. Ventilation inhomogeneity in a1-antitrypsin-deficient emphysema. Eur Respir J 2006; 28: 323-329.
130. Gennimata SA, Palamidas A, Karakontaki F, et al. Pathophysiology of evolution of small airways disease to overt COPD. COPD 2010; 7: 269-275.
131. Paiva M. Gas transport in the human lung. J Appl Physiol 1973; 35: 401-410.
132. Verbanck S, Schuermans D, Van Muylem A, et al. Ventilation distribution during histamine provocation. J Appl Physiol 1997; 83: 1907-1916.
133. Verbanck S, Schuermans D, Meysman M, et al. Noninvasive assessment of airway alterations in smokers: the small airways revisited. Am J Respir Crit Care Med 2004; 170: 414-419.
134. Verbanck S, Schuermans D, Van Muylem A, et al. Conductive and acinar lung-zone contributions to ventilation inhomogeneity in COPD. Am J Respir Crit Care Med 1998; 157: 1573-1577.
135. Verbanck S, Schuermans D, Vincken W. Small airways ventilation heterogeneity and hyperinflation in COPD: response to tiotro-pium bromide. Int J Chron Obstruct Pulmon Dis 2007; 2: 625-634.
136. Verbanck S, Schuermans D, Paiva M, et al. Small airway function improvement after smoking cessation in smokers without airway obstruction. Am J Respir Crit Care Med 2006; 174: 853-857.
137. Verbanck S, Schuermans D, Van Malderen S, et al. The effect of conductive ventilation heterogeneity on diffusing capacity measurement. J Appl Physiol 2008; 104: 1094-1100.
138. Christensson P, Arborelius M Jr, Kautto-Wiberg R. Changes of volume of trapped gas after bronchodilation in subjects with suspected subclinical emphysema. Respiration 1986; 49: 16-22.
139. Horsley A. Lung clearance index in the assessment of airways disease. Respir Med 2009; 103: 793-799.
140. Coxson HO, Mayo J, Lam S, et al. New and current clinical imaging techniques to study chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009; 180: 588-597.
141. Berger P, Perot V, Desbarats P, et al. Airway wall thickness in cigarette smokers: quantitative thin-section CT assessment. Radiology 2005; 235: 1055-1064.
142. Fujimoto K, Kitaguchi Y, Kubo K, et al. Clinical analysis of chronic obstructive pulmonary disease phenotypes classified using high-resolution computed tomography. Respirology 2006; 11: 731-740.
143. Desai SR, Hansell DM, Walker A, et al. Quantification of emphysema: a composite physiologic index derived from CT estimation of disease extent. Eur Radiol 2007; 17: 911-918.
144. Madani A, Zanen J, de Maertelaer V, et al. Pulmonary emphysema: objective quantification at multi-detector row CT - comparison with macroscopic and microscopic morphometry. Radiology 2006; 238: 1036-1043.
145. Akira M, Toyokawa K, Inoue Y, et al. Quantitative CT in chronic obstructive pulmonary disease: inspiratory and expiratory assessment. AJR Am J Roentgenol 2009; 192: 267-272.
146. Matsuoka S, Kurihara Y, Yagihashi K, et al. Quantitative assessment of air trapping in chronic obstructive pulmonary disease using inspiratory and expiratory volumetric MDCT. AJR Am J Roentgenol 2008; 190: 762-769.
147. Nakano Y, Wong JC, de Jong PA, et al. The prediction of small airway dimensions using computed tomography. Am J Respir Crit Care Med 2005; 171: 142-146.
148. Montaudon M, Berger P, Lederlin M, et al. Bronchial morphometry in smokers: comparison with healthy subjects by using 3D CT. Eur Radiol 2009; 19: 1328-1334.
149. Lee YK, Oh YM, Lee JH, et al. Quantitative assessment of emphysema, air trapping, and airway thickening on computed tomography. Lung 2008; 186: 157-165.
150. Madani A, De Maertelaer V, Zanen J, et al. Pulmonary emphysema: radiation dose and section thickness at multi-detector CT quantification - comparison with macroscopic and microscopic morphometry. Radiology 2007; 243: 250-257.
151. Jang YM, Oh YM, Seo JB, et al. Quantitatively assessed dynamic contrast-enhanced magnetic resonance imaging in patients with chronic obstructive pulmonary disease: correlation of perfusion parameters with pulmonary function test and quantitative computed tomography. Invest Radiol 2008; 43: 403-410.
152. Kauczor HU, Hofmann D, Kreitner KF, et al. Normal and abnormal pulmonary ventilation: visualization at hyperpolarized He-3 MR imaging. Radiology 1996; 201: 564-568.
153. van Beek EJ, Dahmen AM, Stavngaard T, et al. Hyperpolarised 3-He MRI versus HRCT in COPD and normal volunteers: PHIL trial. Eur Respir J 2009; 34: 1311-1321.
154. Ohno Y, Koyama H, Nogami M, et al. Dynamic oxygen-enhanced MRI versus quantitative CT: pulmonary functional loss assessment and clinical stage classification of smoking-related COPD. AJR Am J Roentgenol 2008; 190: W93-W99.
155. Bauman G, Puderbach M, Deimling M, et al. Non-contrast-enhanced perfusion and ventilation assessment of the human lung by means of flourier decomposition in proton MRI. Magn Reson Med 2009; 62: 656-664.
156. Roche N, Dalmay F, Perez T, et al. Impact of chronic airflow obstruction in a working population. Eur Respir J 2008; 31: 1227-1233.
157. O'Donnell DE, Laveneziana P, Ora J, et al. Evaluation of acute bronchodilator reversibility in patients with symptoms of GOLD stage I COPD. Thorax 2009; 64: 216-223.
158. Burgel PR, Paillasseur JL, Caillaud D, et al. Clinical COPD phenotypes: a novel approach using principal component and cluster analyses. Eur Respir J 2010; 36: 531-539.
159. Vestbo J, Lange P. Can GOLD stage 0 provide information of prognostic value in chronic obstructive pulmonary disease? Am J Respir Crit Care Med 2002; 166: 329-332.
160. Burgel PR, Martin C. Mucus hypersecretion in COPD: should we only rely on symptoms? Eur Respir Rev 2010; 19: 94-96.
161. Hogg JC, Chu FS, Tan WC, et al. Survival after lung volume reduction in chronic obstructive pulmonary disease: insights from small airway pathology. Am J Respir Crit Care Med 2007; 176: 454-459.
162. Weatherall M, Marsh S, Shirtcliffe P, et al. Quality of life measured by the St George's Respiratory Questionnaire and spirometry. Eur Respir J 2009; 33: 1025-1030.
163. Jensen HH, Godtfredsen NS, Lange P, et al. Potential misclassification of causes of death from COPD. Eur Respir J 2006; 28: 781-785.
164. Cosio BG, Iglesias A, Rios A, et al. Low-dose theophylline enhances the anti-inflammatory effects of steroids during exacerbations of COPD. Thorax 2009; 64: 424-429.
165. Calverley PM, Rabe KF, Goehring UM, et al. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet 2009; 374: 685-694.
166. Fabbri LM, Calverley PM, Izquierdo-Alonso JL, et al. Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials. Lancet 2009; 374: 695-703.
167. Decramer M, Rutten-van Molken M, Dekhuijzen PN, et al. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial. Lancet 2005; 365: 1552-1560.
168. Stav D, Raz M. Effect of N-acetylcysteine on air trapping in COPD: a randomized placebo-controlled study. Chest 2009; 136: 381-386.
169. Sturton RG, Trifilieff A, Nicholson AG, et al. Pharmacological characterization of indacaterol, a novel once daily inhaled 2 adrenoceptor agonist, on small airways in human and rat precision-cut lung slices. J Pharmacol Exp Ther 2008; 324: 270-275.
170. Barnes PJ. Distribution of receptor targets in the lung. Proc Am Thorac Soc 2004; 1: 345-351.
171. Tantucci C, Duguet A, Similowski T, et al. Effect of salbutamol on dynamic hyperinflation in chronic obstructive pulmonary disease patients. Eur Respir J 1998; 12: 799-804.
172. Duranti R, Filippelli M, Bianchi R, et al. Inspiratory capacity and decrease in lung hyperinflation with albuterol in COPD. Chest 2002; 122: 2009-2014.
173. Celli B, ZuWallack R, Wang S, et al. Improvement in resting inspiratory capacity and hyperinflation with tiotropium in COPD patients with increased static lung volumes. Chest 2003; 124: 1743-1748.
174. Corda L, Bertella E, La Piana GE, et al. Inhaled corticosteroids as additional treatment in alpha-1-antitrypsin-deficiency-related COPD. Respiration 2008; 76: 61-68.
175. Calverley PM, Kuna P, Monso E, et al. Beclomethasone/formoterol in the management of COPD: a randomised controlled trial. Respir Med 2010; 104: 1858-1868.
176. Cazzola M, MacNee W, Martinez FJ, et al. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J 2008; 31: 416-469.